SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults. The joint effort combines SandboxAQ’s proven software and biologics technology for drug candidate identification and lead optimization with iOncologi’s deep tech immunotherapy design and clinical expertise to overcome longstanding barriers in brain cancer treatment.

Because treatment options are limited, people diagnosed with glioblastoma usually survive less than two years. This aggressive cancer accounts for about 15% of all primary brain tumors, about 300,000 new cases and more than 200,000 deaths worldwide each year, according to the World Health Organization.